EUVIMEDObjevte EUVIMED
Systematische ÜbersichtMetaanalyseOpen access · CC BY-NC-ND 4.0

Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta‐analysis

Dahyeon Lee, Gayeong Seo iD, Yunha Kim iD, Jea Young Min iD, Jeong Yee iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16635 ↗

At a glance

Systematische Übersicht in Diabetes, Obesity and Metabolism, 2025. Written by Dahyeon Lee and 4 co-authors. Institution: School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Ketoacidosis, Diabetes Mellitus, Type 2. Cited 8 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Aims

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are effective antihyperglycaemic agents; however, they also increase the risk of diabetic ketoacidosis (DKA). As the clinical evidence comparing DKA features between SGLT2i users and non‐users remains limited due to the low incidence of DKA, this study aimed to compare the clinical features and outcomes of DKA in SGLT2i users and non‐users by conducting a systematic review and meta‐analysis. Materials and Methods Relevant studies were searched in PubMed, Scopus, and Web of Science in February 2025. Studies that compared the clinical features or outcomes of DKA between SGLT2i users and non‐users were included. Pooled estimates were derived using odds ratios for binary variables and mean differences for continuous variables.

Results

A total of 9 studies were analysed. DKA cases in SGLT2i users had lower odds of prior DKA and insulin use. Compared with DKA cases in non‐users, SGLT2i users had lower glucose, HbA1c, creatinine, and lactate levels. No significant differences were found in the length of hospitalisation, intensive care unit admission, or in‐hospital mortality.

Conclusions

These findings provide quantitative evidence of the distinct clinical features of SGLT2i‐associated DKA, which may aid in early detection, management, and prevention in clinical practice.

Subjects

MeSH terms (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic KetoacidosisDiabetes Mellitus, Type 2HumansTreatment OutcomeHypoglycemic Agents

Author keywords

SGLT2 inhibitordiabetes complicationsmeta‐analysistype 2 diabetes

Substances

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Authors and institutions

  • School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.

ORCID profiles: Gayeong Seo, Yunha Kim, Jea Young Min, Jeong Yee

Cite

APA

Lee, D., Seo, G., Kim, Y., Min, J. Y., & Yee, J. (2025). Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16635

Vancouver

Lee D, Seo G, Kim Y, Min JY, Yee J. Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16635

BibTeX
@article{Lee2025,
  author = {Lee, Dahyeon and Seo, Gayeong and Kim, Yunha and Min, Jea Young and Yee, Jeong},
  title = {Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta‐analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16635}
}
Start for free →